Skip to main content
. 2019 Apr 5;11:80. doi: 10.3389/fnagi.2019.00080

Figure 2.

Figure 2

Dose-dependent neuroprotection of purified standard bvPLA2 on motor deficits in MPTP-injected mice. (A) Standard bvPLA2 purified from BV (0.01, 0.1, or 0.5 mg/kg), commercial standard bvPLA2 (Com. bvPLA2; 0.5 mg/kg), inactive recombinant mutant bvPLA2 (bvPLA2-H34A; 0.5 mg/kg), or standard melittin purified from BV (0.5 mg/kg) was administered to the mice for 6 days, beginning 1 day after MPTP injection. (B,C) The motor ability of mice was evaluated on a pole test on day 6 post-MPTP. Time to orient downward (B) and total time to descend (C) were measured. The data are expressed as the means ± SEM, n = 5–8 per group; *p < 0.05, **p < 0.01, ***p < 0.001, ns, not significant.